ArticleThe journal of applied laboratory medicine2020
Biomarkers of Alzheimer Disease.
Article in The journal of applied laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05604183 (Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease
Who cites it
28 citing papers in PubMed, 52 citations in OpenAlex.
- Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease.Alzheimer's research & therapy · 2022Trial
- Spatiotemporal characterization of Alzheimer disease pathology in living human brain tissue.Nature communications · 2026Article
- Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment.AIMS neuroscience · 2026Review
- Proteome-Based Biomarkers for Alzheimer's Disease: Old Acquisitions and Innovative Proposals.International journal of molecular sciences · 2025Review
- Suggestions for the decision making in subjective cognitive complaints.Aging clinical and experimental research · 2025Review
- Article
- Disease Progression Modeling and Stratification for detecting sub-trajectories in the natural history of pathologies: Application to Alzheimer's disease trajectory modeling.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Biomarkers Unveiling the Interplay of Mind, Nervous System, and Immunity.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Analysis of Brain Protein Stability Changes in a Mouse Model of Alzheimer's Disease.Journal of proteome research · 2024Article
- AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring.Biosensors · 2024Review
- Cerebral perivascular spaces as predictors of dementia risk and accelerated brain atrophy.medRxiv : the preprint server for health sciences · 2024Article
- Article
- Multi-peptide characterization of plasma neurofilament light chain in preclinical and mild Alzheimer's disease.Brain communications · 2024Article
- Review of Phytochemical Potency as a Natural Anti-Molecules (Basel, Switzerland) · 2023Review
- Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease.Cellular and molecular neurobiology · 2023Review
- Advances in sample preparation and HPLC-MS/MS methods for determining amyloid-β peptide in biological samples: a review.Analytical and bioanalytical chemistry · 2023Review
- Immunological evaluation of patients with Alzheimer's disease based on mitogen-stimulated cytokine productions and mitochondrial DNA indicators.BMC psychiatry · 2023Article
- The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review.Alzheimer's research & therapy · 2022Review
- Perspectives and challenges in patient stratification in Alzheimer's disease.Alzheimer's research & therapy · 2022Review
- Alzheimer's disease clinical trial update 2019-2021.Journal of neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAlzheimer disease (AD) was once a clinical diagnosis confirmed by postmortem autopsy. Today, with the development of AD biomarkers, laboratory assays to detect AD pathology are able to complement clinical diagnosis in symptomatic individuals with uncertain diagnosis. A variety of commercially available assays are performed as laboratory-developed tests, and many more are in development for both clinical and research purposes. CONTENT: The role of laboratory medicine in diagnosing and managing AD is expanding; thus, it is important for laboratory professionals and ordering physicians to understand the strengths and limitations of both existing and emerging AD biomarker assays. In this review, we will provide an overview of the diagnosis of AD, discuss existing laboratory assays for AD and their recommended use, and examine the clinical performance of emerging AD biomarkers. SUMMARY: The field of AD biomarker discovery and assay development is rapidly evolving, with recent studies promising to improve both the diagnosis of symptomatic individuals and enrollment and monitoring of asymptomatic individuals in research studies. However, care must be taken to ensure proper use and interpretation of these assays. For clinical purposes, these assays are meant to aid in diagnosis but are not themselves diagnostic. For individuals without symptoms, AD biomarker tests are still only appropriate for research purposes. Additionally, there are analytical challenges that require careful attention, especially for longitudinal use of AD tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.